Clinical Trial Update: Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for pemigatinib in solid tumors with FGF/FGFR alterations; status and conditions are reported but final results are not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Solid Tumor, FGF Receptor Gene Mutation | Phase 2 | Status: UNKNOWN